Pfizer Acquires a GLP-1 Pipeline and Revives FOMO Corporate Strategy Discussing Pfizer's savvy acquisition of Metsera and critiquing the GLP-1 'gap analysis' many outsiders promote as a reason all the Big Pharmas will be in GLP-1 On Monday, Pfizer PFE 0.00% announced it is acquiring Metsera MTSR 0.00% and its obesity pipeline
For research use only.
All three conditions, obesity without eating disorders, obesity with BED, and BN, are characterized by disruptions in appetite regulation, reward processing, and metabolic homeostasis
The treatment normalized serum corticosterone levels, enhanced central GABA and serotonin concentrations and reduced peripheral inflammation and gut microbiota profiling revealed a reduction in potentially pathogenic genera ( Acinetobacter, Enterococcus, Bacillus ) and increased abundance of beneficial taxa ( Muribaculum, Alistipes, Lactobacillus ), indicating the therapeutic potential of targeted psychobiotic intervention for stress-related disorders (Tyagi et al., 2025)
This guide explains the benefits, price in Pakistan, correct dosage, ingredients and how to verify the original product before buying